Lenalinomide, which has been tested in SLE clinical trials (18), and the c-met-HGFR (hepatocyte growth factor receptor) inhibitor pf-04217903 (19) might also be considered as treatment options for G1 SLE patients. This evidence concerns the gene MET and systemic lupus erythematosus.